Hyponatraemia: more than just a marker of disease severity? - PubMed (original) (raw)

Review

Hyponatraemia: more than just a marker of disease severity?

Robert W Schrier et al. Nat Rev Nephrol. 2013 Jan.

Erratum in

Abstract

Hyponatraemia--the most common serum electrolyte disorder--has also emerged as an important marker of the severity and prognosis of important diseases such as heart failure and cirrhosis. Acute hyponatraemia can cause severe encephalopathy, but the rapid correction of chronic hyponatraemia can also profoundly impair brain function and even cause death. With the expanding elderly population and the increased prevalence of hyponatraemia in this segment of society, prospective studies are needed to examine whether correcting hyponatraemia in the elderly will diminish cognitive impairment, improve balance and reduce the incidence of falls and fractures. Given that polypharmacy is also common in the elderly population, the various medications that may stimulate arginine vasopressin release and/or enhance the hormone's action to increase water absorption must also be taken into consideration. Whether hyponatraemia in a patient with cancer is merely a marker of poor prognosis or whether its presence may alter the patient's quality of life remains to be examined. In any case, hyponatraemia can no longer be considered as just a biochemical bystander in the ill patient. A systematic diagnostic approach is necessary to determine the specific aetiology of a patient's hyponatraemia. Therapy must then be dictated not only by recognized reversible causes such as advanced hypothyroidism, adrenal insufficiency, diuretics or other medicines, but also by whether the hyponatraemia occurred acutely or chronically. Information is emerging that the vast majority of cases of hyponatraemia are caused by the nonosmotic release of arginine vasopressin. Now that vasopressin V2-receptor blockers are available, a new era of clinical investigation is necessary to examine whether hyponatraemia is just a marker of severe disease or whether correction of hyponatraemia could improve a patient's quality of life. Such an approach must involve prospective randomized studies in different groups of patients with hyponatraemia, including those with advanced heart failure, those with cirrhosis, patients with cancer, and the elderly.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ann Intern Med. 1983 Aug;99(2):185-8 - PubMed
    1. Pediatrics. 2003 Feb;111(2):227-30 - PubMed
    1. Hepatology. 1998 Sep;28(3):851-64 - PubMed
    1. J Card Fail. 2012 Jan;18(1):74-81 - PubMed
    1. Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2428-34 - PubMed

Publication types

MeSH terms

LinkOut - more resources